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Purpose: Stage III non-small cell lung cancer (NSCLC) patients with poor performance
status (PS) or co-morbidities are often not candidates for standard chemoradiotherapy
(chemoRT) due to poor tolerance to treatments. A pilot study for poor-risk stage III NSCLC
patients was conducted combining cetuximab, a chimeric monoclonal antibody targeting
epidermal growth factor receptor (EGFR), with chest radiation (RT).
Methods: Stage III NSCLC patients with Zubrod PS 2, or Zubrod PS 0–1 with poor
pulmonary function and co-morbidities prohibiting chemoRT were eligible. A loading
dose of cetuximab (400 mg/m2) was delivered week 1, followed by weekly cetuximab
(250 mg/m2)/RT to 64.8 Gy in 1.8 Gy daily fractions, and maintenance weekly cetuximab
(250 mg/m2) for 2 years or until disease progression. H-score for EGFR protein expression
was conducted in available tumors.
Results: Twenty-four patients were enrolled. Twenty-two were assessed for outcome
and toxicity. Median survival was 14 months and median progression-free survival was
8 months. The response rate was 47% and disease control rate was 74%. Toxicity assess-
ment revealed 22.7% overall ≥Grade 3 non-hematologic toxicities. Grade 3 esophagitis
was observed in one patient (5%).The skin reactions were mostly Grade 1 or 2 except two
of 22 (9%) had Grade 3 acne and one of 22 (5%) had Grade 3 radiation skin burn. Grade
3–4 hypomagnesemia was seen in four (18%) patients. One patient (5%) had elevated
cardiac troponin and pulmonary emboli. H-score did not reveal prognostic significance. An
initially planned second cohort of the study did not commence due to slow accrual, which
would have added weekly docetaxel to cetuximab/RT after completion of the first cohort
of patients.
Conclusion: Concurrent weekly cetuximab/chest RT followed by maintenance cetuximab
for poor-risk stage III NSCLC was well tolerated. Further studies with larger sample sizes
will be useful to establish the optimal therapeutic ratio of this regimen.
Keywords: cetuximab, stage III non-small cell lung cancer, EGFR, performance status, radiosensitization
INTRODUCTION
Multiple randomized phase 3 clinical studies have demonstrated
the superiority of combination chemoradiation (chemoRT) to
radiotherapy (RT) alone for inoperable stage III non-small cell
lung cancers (NSCLC) (1–8). These clinical trials generally have
selected patients with good performance status (PS) and no major
medical co-morbidities or weight loss. Consequently, combina-
tion thoracic radiation (RT) and platinum-based chemotherapy
has become the standard treatment approach for this patient
population.
However, in everyday oncologic practice, stage III NSCLC
patients with poor PS and/or co-morbidities are often not candi-
dates for standard combination chemoRT due to poor tolerance,
increased toxicities, and uncertainty of a survival benefit. Thus, the
treatment of this fragile yet common subset of stage III inoperable
NSCLC has been a clinical challenge. Recognizing this unmet need,
The Southwest Oncology Group (SWOG) has conducted a series
of clinical trials with modified chemoRT regimens with the intent
to identify a tolerable and effective regimen for poor-risk stage
III NSCLC patients. Two pilot studies by SWOG were conducted.
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S9429 evaluated a regimen of RT with concurrent etoposide and
the substitution of carboplatin for cisplatin, and S9712 evalu-
ated low-dose weekly paclitaxel and carboplatin with concurrent
RT followed by consolidation paclitaxel. S9429 yielded a median
survival of 13 months, while S9712 yielded a median survival of
10.3 months. The lower survival time in S9712 was attributed to a
7% treatment-related death rate (9, 10).
With proven efficacy and mild toxicity observed with the epi-
dermal growth factor receptor (EGFR) pathway targeting agents
(monoclonal antibodies and tyrosine kinase inhibitors) for the
treatment of advanced NSCLC, these agents seem ideal to explore
as alternatives to cytotoxic chemotherapeutic agents in the treat-
ment of stage III NSCLC patients with poor-risk features. Cetux-
imab, a chimerized antibody to EGFR, is attractive because of its
proven radiosensitizing properties in head and neck cancer (11).
In addition, cetuximab in combination with chemotherapy has
demonstrated a modest survival gain compared with chemother-
apy alone in a phase 3 trial for chemotherapy-naive patients with
EGFR-expressing advanced stage NSCLC (median survival 11.3
vs. 10.1 months, p= 0.044) (12). In comparison with cytotoxic
chemotherapy, the side effects of cetuximab are relatively mild,
usually limited to rash, fatigue, and low magnesium levels.
Given the known benefit of adding systemic therapy to RT in
this disease setting, evaluation of a radiosensitizing agent that is
devoid of the traditional toxicities of chemotherapy is an attrac-
tive approach in poor-risk stage III NSCLC patients. The primary
objectives of our study were to assess the feasibility and toxic-
ity of weekly cetuximab and concurrent chest RT. The secondary
objectives were to evaluate the response rate as well as overall
(OS) and progression-free survival (PFS). If this regimen were
to prove feasible and well tolerated, the plan was to add weekly
low-dose docetaxel (20 mg/m2) to the regimen in a second cohort
of patients. We also conducted preliminary EGFR IHC receptor
analyses to gain information on the relationship between EGFR
expression and survival/PFS in this study cohort with the limited
sample size.
MATERIALS AND METHODS
This was a National Cancer Institute (NCI) cooperative group trial
administered through SWOG. The treatment protocol (clinical-
trials.gov identifier: NCT00288054) was approved by institutional
review boards at each participant site. All patients enrolled in the
study provided oral and written informed consent.
PATIENT ELIGIBILITY
Adult patients with newly diagnosed and pathologically confirmed
inoperable stage IIIA or IIIB NSCLC according to AJCC TNM
staging 6th edition (13), defined as poor-risk for chemoRT based
on SWOG criteria, were eligible. These included patients with a
Zubrod PS 2 had to have FEV1> 800 ml and corrected DLCO
≥8 ml/mmHg/min; and patients with Zubrod PS 0–1 had to have
pulmonary function (FEV 1< 2 l) and co-morbidities prohibit-
ing chemoRT. All patients were required to have adequate hepatic
and hematologic labs, and a calculated creatinine clearance of
≥20 ml/min. Exclusion criteria included patients with malignant
pleural effusion (wet IIIB) or any distant metastasis; patients with
prior chemotherapy, surgery, or radiotherapy for this diagnosis;
patients with adenocarcinoma-in situ (bronchioloalveolar carci-
noma), stage IIIB tumor involving the superior sulcus (Pancoast)
tumors (due to a competing SWOG protocol S0220 for Pancoast
tumors); and patients with medical illnesses including but not
limited to active infection, unstable congestive heart failure, active
angina, unstable cardiac arrhythmias, and peptic ulcer disease
uncontrolled by appropriate treatments.
STUDY DESIGN
The design was a dose escalation study with two cohorts. The ini-
tial 27 patients enrolled were to receive a regimen of cetuximab and
concurrent daily chest RT followed by maintenance cetuximab. If
the regimen of concurrent cetuximab and chest RT was well tol-
erated, the study would then move forward to the second cohort
with concurrent cetuximab, chest RT, weekly low-dose docetaxel,
and maintenance cetuximab.
PRETREATMENT EVALUATIONS
Pretreatment evaluation included a complete medical history
and physical examination including PS, weight, CT of chest and
abdomen, PET scan, laboratory analysis (CBC with differentia-
tion, electrolyte and blood chemistry, liver enzymes, magnesium,
and LDH), pulmonary function tests, brain scan, ECG if indicated,
and a bone scan if clinically indicated.
CETUXIMAB TREATMENT
A loading dose of cetuximab at 400 mg/m2 over a 2-h infusion was
given during the first week. Chest radiation started the second week
with concurrent weekly cetuximab at 250 mg/m2 over a 1-h IV
infusion. All patients were premedicated with diphenhydramine
50 mg IV prior to the first dose. Premedication was recommended
prior to subsequent doses. The dose of diphenhydramine could be
reduced at the treating physician’s discretion. Maintenance weekly
cetuximab at 250 mg/m2 continued until disease progression or
for 2 years after completion of concurrent chest RT.
CETUXIMAB DOSE MODIFICATIONS
Dose modifications for future cetuximab infusions were instituted
in case of severe acneiform rash (Grade 3). No dose modifica-
tion was required for Grade 1 or 2 rash. Treatment with topical
and/or oral antibiotics was considered at the discretion of the treat-
ing physician. Topical corticosteroids were not recommended. For
Grade 2 rash that was unacceptable to the patient for symptomatic
reasons, cetuximab was held until resolution to ≤Grade 1 for up
to 4 weeks. For Grade 3 skin reaction of the first occurrence, cetux-
imab treatment was delayed for 1–2 weeks. If the toxicity resolved
to≤Grade 2, treatment may be resumed without a change in dose
level. If the toxicity did not resolve, to ≤Grade 1 after 4 weeks,
protocol treatment was discontinued. For any second occurrences
of a Grade 3 skin reaction, cetuximab treatment was delayed for
1–2 weeks. If the toxicity resolved to ≤Grade 2, treatment was re-
initiated at 200 mg/m2. If the toxicity did not resolve to≤Grade 1
after 4 weeks, protocol treatment was discontinued. For the third
occurrence of a Grade 3 skin reaction, cetuximab therapy was
delayed for 1–2 weeks. If the toxicity resolved to ≤Grade 2, treat-
ment was re-initiated at 150 mg/m2. If the toxicity did not resolve
to≤Grade 1 after 4 weeks, protocol treatment was discontinued. If
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there was a fourth occurrence of a Grade 3 skin reaction, protocol
treatment was discontinued.
CHEST RADIATION
Radiation began on week 2 (week 1 was for the loading dose
of cetuximab) and continued through 7.5 weeks. All treatments
were based on CT simulation with corrections for tissue inho-
mogeneity. Gross tumor volume (GTV) was defined as all gross
disease including the primary tumor and clinically involved lymph
nodes (≥1.5 cm by CT scan, PET positive, or physical exam, or
biopsy positive). The clinical tumor volume was defined as GTV
with 1.5 cm margins. The planning treatment volume (PTV) was
the GTV with 2-cm margins (CTV=GTV+ 1.5 cm margins, and
PTV=CTV+ 0.5 cm margins). The PTV could be treated with
any combination of coplanar or non-coplanar three-dimensional
(3D) conformal fields shaped to deliver the specified dose while
restricting the dose to the normal tissues. The treatment plan
used for each patient was based on an analysis of the volumet-
ric dose including the dose volume histogram (DVH) analyses of
the PTV and critical normal structures. Standard normal tissue
constraints were applied. In cases with extensive atelectasis and/or
pneumonia where tumor margins were obscure, field boundaries
were left to the judgment of the treating radiation oncologist. RT
prescription was PTV to 64.8 Gy in 36 fractions given 5 days a
week, 1.8 Gy/day. The dose was prescribed to the isocenter. The
dose within the PTV could not vary by more than ±10% of the
stated target dose. Prophylactic mediastinal, contralateral hilar, or
supraclavicular lymph node radiation was not allowed. Intensity
modulated radiation therapy (IMRT) was not allowed. V20 (per-
cent lung volume receiving at least 20 Gy radiation dose) on the
radiation treatment plan needed to be ≤30%.
FOLLOW-UP EVALUATIONS
Toxicity, PS, body weight, blood counts, and electrolytes were eval-
uated weekly during the concomitant weekly cetuximab radiation
period. Post-radiation evaluation included medical history and
physical examination including PS, body weight, lab test, and tox-
icity evaluation at weeks 10, 14, 18, and 22. After week 22, the
monitoring continued once every 3 months with the additional
inclusion of CT of chest and abdomen, PET scan if indicated, and
brain scan if indicated.
TUMOR RESPONSE EVALUATION
Objective response was recorded at each evaluation with the
Response Evaluation Criteria in Solid Tumors (RECIST) crite-
ria: (a) Complete Response (CR): complete disappearance of all
measurable and non-measurable disease. No new lesions. No
disease-related symptoms. (b) Partial Response (PR): applied only
to patients with at least one measurable lesion and≥30% decrease
from baseline of the sum of longest diameters of all target mea-
surable lesions. No unequivocal progression of non-measurable
disease. No new lesions. All target measurable lesions must be
assessed using the same techniques as baseline. (c) Stable Disease:
not qualifying for CR, PR, or progression. All target measurable
lesions must be assessed using the same techniques as baseline.
(d) Progression: one or more of the following must occur: 20%
increase in the sum of longest diameters of target measurable
lesions over smallest sum observed (over baseline if no decrease
during therapy) using the same techniques as baseline (14).
EGFR PROTEIN EXPRESSION (IHC WITH DAKO pharmDx)
One slide per patient was stained with Dako pharmDx EGFR anti-
body. One H&E slide for each patient was received for pathologic
review as well. The methodology for EGFR IHC analysis has been
previously reported (12, 15, 16). Specimen evaluation was per-
formed by a certified pathologist. The preferable number of viable
tumor cells in order to qualify for IHC assessment was 50. However,
when there were less than 50 cells but more than 20 they were eval-
uated and a notation was made in the comments section. Tumors
were evaluated by two different methods. In the first method, only
the membrane staining, whether or not it was completely circum-
ferential, was considered and the percent of total tumor cells within
each staining intensity category [0 (no staining), 1+ (weak), 2+
(moderate), 3+ (strong)] was reported (15, 16). In the second
method, the cytoplasm was evaluated and the percent of total
tumor cells within each staining intensity category [0 (no stain-
ing), 1+ (weak), 2+ (moderate), 3+ (strong)] was reported (15,
16). A hybrid-(H) score was generated based on the fraction of
staining cells in each intensity category. The H-score was calcu-
lated by completing the formula (% cells of 0 intensity× 0)+ (%
cells of 1+ intensity× 1)+ (% cells of 2+ intensity× 2)+ (% cells
of 3+ intensity× 3). This produces a final H-score with a range
from 0 to 300.
STATISTICAL METHODS
The objective of this study was to assess the feasibility and toxicity
experience for poor-risk stage III NSCLC patients treated with the
study regimen. The primary endpoint was defined as the rate of
Grade 3 or greater esophagitis or pneumonitis within 4 months
after discontinuation of radiation therapy.
The design was a dose escalation study with two cohorts. The
initial 27 patients enrolled were to receive a regimen of cetux-
imab and concurrent RT with no docetaxel, and with mainte-
nance cetuximab for 2 years or until disease progression. If 10 or
fewer patients experienced either Grade 3 or greater esophagitis or
pneumonitis within 4 months after discontinuation of radiation
therapy, a subsequent cohort of 27 patients would be enrolled to
receive a regimen of cetuximab, concurrent RT, plus docetaxel
(20 mg/m2) followed by maintenance cetuximab as described.
For each cohort of 27 patients, the toxicity of the regimen
would be considered unacceptable if 11 or more patients expe-
rienced either Grade 3 or greater esophagitis or pneumonitis
within 4 months after discontinuation of radiation therapy. This
design was sufficient to distinguish between the null hypothesis
that the dose is unsafe (≥55% of patients experiencing Grade 3
or greater esophagitis or pneumonitis toxicity) vs. the alterna-
tive of a safe dose (<30% with Grade 3 or greater esophagitis
or pneumonitis toxicity) with 84% power, using a one-sided
test based on the binomial distribution with a significance level
of 5%.
Adverse events were assessed according to the CTCAE (NCI
Common Terminology Criteria for Adverse Events) Version 3.0.
Only events that were reported as possibly, probably, or definitely
related to protocol treatment were included in this analysis.
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Progression-free survival and OS were estimated using the
Kaplan–Meier method (17). Confidence intervals for the median
PFS and median OS were constructed using the Brookmeyer and
Crowley methods (18).
An exploratory analysis was performed to investigate the rela-
tionship between EGFR protein expression, as measured by H-
score, and clinical outcomes. The association with PFS and OS
was evaluated using a two-sided log-rank statistic.
RESULTS
The study was open to accrual from April 1, 2006 to May 15, 2009,
a duration of 37 months. The study was closed early due to poor
accrual. Twenty-four patients were enrolled in the first cohort and
received cetuximab+RT with no docetaxel. Two patients were
considered ineligible due to having a baseline FEV 1> 2 l. Base-
line patient characteristics are shown in Table 1. Twenty patients
(91%) received the planned radiation dose. Six patients (27%)
had cetuximab dose reductions during concurrent RT. Eighteen
patients went on to receive maintenance therapy with cetuximab.
The median number of cetuximab cycles during maintenance was
5.5 (range: 1–23 cycles).
SAFETY ANALYSIS
All 22 eligible patients were assessed for adverse events (AEs). Toxi-
city assessment revealed 22.7% overall≥Grade 3 non-hematologic
toxicity. One patient had Grade 3 treatment-related esophagitis,
and no patients had ≥Grade 3 pneumonitis. Therefore, the esti-
mated rate of Grade 3 or greater pneumonitis/esophagitis was
5% (95% confidence interval: 0–23%). Table 2 summarizes other
treatment-related AEs of interest. AEs potentially related to cetux-
imab included the following: two of 22 (9%) had Grade 3 acne, one
of 22 (5%) had Grade 3 skin burn. There was a Grade 3 (5%) hypo-
magnesemia and 2 (9%) Grade 4 hypomagnesemia. There was no
Grade 3 rash. There was one patient with Grade 4 AE with elevated
cardiac troponin in a patient who had pulmonary embolism. Most
other AEs were Grade 1 and/or 2. There were no treatment-related
deaths among the above-mentioned three patients (14%) who had
experienced treatment-related Grade 4 adverse events.
TUMOR RESPONSE
Nineteen patients had measurable disease at baseline and were
included in the analysis of response. Nine patients had either a
confirmed (7) or unconfirmed (2) PR for a response rate of 47%
(95% confidence interval: 24–71%), with a median duration of
6 months. Five additional patients had a best response of stable
disease for a disease control rate of 74% (95% confidence inter-
val: 41–91%). The other five patients included two patients with
increasing disease, and three patients who could not have their
exact response determined due to inadequate disease assessments
but were included in the denominator as non-responders. This
study utilized the RECIST 1.0 criteria and response was assessed
only in those patients with measurable disease at baseline.
SURVIVAL
As of April 11, 2012, four patients remained alive with a median
follow-up of 25 months (range: 17–32 months). Kaplan–Meier OS
estimate at 1-year survival was 55% (95% confidence interval:
Table 1 | Patient characteristics (N =22).
N Percentage
AGE
Median (range) 72.9 (51.3–84.5) –
GENDER
Male 11 50
Female 11 50
RACE
White 20 91
Black 1 4.5
Asian 1 4.5
PERFORMANCE STATUS
0 2 9
1 15 68
2 5 23
SMOKING HISTORY
Current 9 41
Former 12 54.5
Never 1 4.5
TUMOR STAGE
IIIA 12 55
IIIB 10 45
WEIGHT LOSS
<5% 13 59
5≤10% 5 23
10–20% 3 14
>20% 0 0
Not reported 1 5
FEV1
≥2L 19 86
≥1–<2L 2 9
Not reported 1 5
Albumin: median (range) 4.0 (2.7–4.9) –
32–72%) and the median OS estimate was 14 months (95% con-
fidence interval: 8–24 months) (Figure 1). The estimated 1-year
PFS was 18% (95% confidence interval: 6–36%) and the estimated
median PFS was 8 months (95% confidence interval: 5–9 months)
(Figure 2).
EGFR PROTEIN EXPRESSION ANALYSIS
As none of the patients in this study received chemotherapy as part
of the regimen, this study population represented a unique cohort
and opportunity to assess if EGFR expression affected outcome in
patients treated with the combination of radiation and cetuximab
only. We were aware of the limitation of the small sample size of
this study population, thus this is an exploratory analysis. Tumor
samples from 11 patients were assayed with IHC using Dako phar-
mDx. As none of the reported H-scores were at least 200, the
data were dichotomized by splitting on H-score ≥100 vs. <100.
Analysis of this small cohort of cases did not demonstrate any cor-
relation between Membrane H-score and OS (p= 0.76) and PFS
(p= 0.39),or between Cytoplasmic H-score and OS (p= 0.59) and
PFS (p= 0.87). The tumor histology, membrane, and cytoplasm
H-scores vs. PFS, and OS are shown in Table 3.
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Table 2 | Adverse events (CTCAEVersion 3.0).
Grade 1 N (%) Grade2 N (%) Grade 3 N (%) Grade 4 N (%) Grade 5 N (%)
Pneumonitis 1 (5) 4 (18) 0 0 0
Esophagitis 4 (18) 3 (14) 1 (5) 0 0
Cardiac troponin I 0 0 0 1 (5) 0
Thrombosis/embolism 0 0 0 1 (5) 0
Hypomagnesemia 3 (14) 0 1 (5) 2 (9) 0
Dry eye 1 (5) 0 0 0 0
Nail changes 0 2 (9) 0 0 0
Allergic reaction 0 2 (9) 1 (5) 0 0
Fatigue 8 (36) 5 (23) 1 (5) 0 0
Weight loss 2 (9) 2 (9) 0 0 0
SKIN REACTIONS
Acne 7 (32) 6 (27) 2 (9) 0 0
Burn 0 0 1 (5) 0 0
Dry skin 3 (14) 0 0 0 0
Pruritus/itching 3 (14) 1 (5) 0 0 0
Rash/RT dermatitis 3 (14) 4 (18) 0 0 0
GASTROINTESTINAL
Diarrhea 4 (18) 2 (9) 1 (5) 0 0
Dysphagia 4 (18) 3 (14) 0 0 0
Odynophagia 2 (9) 0 0 0 0
HEMATOLOGIC
Hemoglobin 4 (18) 4 (18) 0 0 0
Lymphopenia 0 1 (5) 4 (18) 0 0
Neutrophils 0 1 (5) 1 (5) 0 0
Platelets 2 (9) 0 0 0 0
RESPIRATORY SYMPTOMS
Cough 3 (14) 1 (5) 1 (5) 0 0
Dyspnea 4 (18) 1 (5) 3 (14) 0 0
Hypoxia 0 0 1 (5) 0 0
FIGURE 1 | A plot of Kaplan–Meier estimates of overall survival (OS) of
patients treated with concurrent cetuximab and chest radiation. OS
was defined as the time from the date of enrollment until the date of death
due to any cause. Patients last known to be alive were censored at the date
of last contact and are marked on the curve with a tic representing the last
follow-up time.
DISCUSSION
While many randomized phase 3 studies have established com-
bination chemoRT treatment as a standard of care for stage III
NSCLC patients with good PS, there is no consensus for the treat-
ment of patients with poor-risk features. Outcomes from the two
previous SWOG studies, S9429 and S9712, highlight the obstacles
of treating poor-risk stage III NSCLC. Balancing therapy inten-
sity with tolerability remains a major challenge. Experience from
S9429 and S9712 support the conclusion that concurrent cytotoxic
chemotherapy and radiotherapy may not be optimal for the treat-
ment of poor-risk stage III NSCLC patients due to toxicities from
therapies.
There are pre-clinical and clinical data supporting the combi-
nation of radiation treatment with cetuximab. Pre-clinical studies
have demonstrated radiosensitizing effects of cetuximab using
lung cancer cell lines in vitro, and in vivo using human lung cancer
xenografts transplanted into mice (19, 20). A phase 3, randomized
clinical study for head and neck cancers has demonstrated that
cetuximab enhanced radiation treatment effects and improved
both local-regional cancer control and survival (11). Both the pre-
clinical findings and the clinical study in head and neck cancer lend
support to the rationale of combining cetuximab with radiation
treatment in enhancing radiation effects.
Our study combining cetuximab and chest radiotherapy did
show that concurrent cetuximab and chest radiotherapy was well
tolerated. Toxicity assessment revealed 22.7% overall ≥Grade 3
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non-hematologic toxicity. Grade 3 esophagitis was observed in
one patient (5%). The skin reactions were mostly Grade 1 or 2
except two of 22 (9%) had Grade 3 acne and one of 22 (5%) had
Grade 3 radiation skin burn. Grade 3–4 hypomagnesemia was seen
in four (18%) patients. One patient (5%) had elevated cardiac tro-
ponin and pulmonary emboli. We do caution the interpretation
of the observed low rate of Grade 3 esophagitis, since the proba-
bility and severity of esophagitis is dependent on esophageal dose
and volume, and we do not have information on these parame-
ters. There were no treatment-related deaths. We note no Grade
3 pneumonitis in this study, which may attribute to our stringent
normal lung allowance dose of V20 to 30%, compared with most
chemoRT studies using 35% as the upper limit. It is also possible
that the limitation of V20 to 30% might have selected out some
patients with much larger tumor volumes.
FIGURE 2 | A plot of Kaplan–Meier estimates of progression-free
survival (PFS) of patients treated with concurrent cetuximab and chest
radiation. PFS was defined as the time from the date of enrollment until
the date of first documentation of disease progression (per RECIST),
symptomatic deterioration, or death due to any cause. Patients last known
to be alive and progression-free were censored at the date of last contact
and are marked on the curve with a tic representing the last follow-up time.
The FLEX study randomized 1125 patients with advanced
NSCLC to chemotherapy plus cetuximab vs. chemotherapy alone
and showed improved OS of chemotherapy plus cetuximab arm
(HR 0.87). EGFR protein expression by the H-score assessment
was conducted in samples from 1121 patients and showed that
high EGFR expression was associated with longer survival in the
chemotherapy plus cetuximab group than the chemotherapy alone
group (median survival 12.0 vs. 9.6 months, HR= 0.73, p< 0.05)
with the H-score cut-off value of 200 (15). Surprisingly, in our
exploratory study, no patients had a H-score ≥200, which in the
FLEX study constituted approximately one third of the patients.
When we used an H-score of 100 as cut-off, we did not note a
significant difference in survival outcome of patients. The lack of
power to discern real differences is expected given the small sample
size, unless the association is “highly specific” as was seen in the
association between EGFR mutation and the response to EGFR
tyrosine kinase inhibitor reported by Lynch et al. (21), when a
definite association was detected with a total sample size of 16
(eight of nine responders with EGFR mutation and none of seven
non-responders had the mutation).
There are other clinical studies seeking optimal therapy for
either the elderly or the poor-risk patients with stage III NSCLC.
Atagi et al. (22) reported the outcome of thoracic radiotherapy
with or without daily low-dose carboplatin in elderly patients with
NSCLC in a randomized, controlled phase 3 trial by the Japan Clin-
ical Oncology Group (JCOG0301). The study allowed for ECOG
PS 0–2. Patients older than 70 years with unresectable stage III
NSCLC were assigned to chemoRT (60 Gy) plus low-dose carbo-
platin (30 mg/m2/day, 5 days a week for 20 days) or RT alone. They
reported a median survival of 22.4 months for the chemoRT arm,
and 16.9 months for the RT alone arm. Grade 3–4 hematologic
toxic effects were similar between the two groups. The incidences
of Grade 3–4 pneumonitis and late lung toxicity were similar
between groups as well. There were seven treatment-related deaths:
3 of 100 patients (3%) in the chemoRT group and 4 of 100 (4%)
in the RT group. Ready et al. (23) reported a study of two cycles
of induction paclitaxel 200 mg/m2 and carboplatin AUC 6, plus
gefitinib 250 mg daily in patients with stage III NSCLC. Poor-risk
Table 3 | Histology, membrane, and cytoplasm H-scores vs. tumor response, PFS, and OS.
Case Histology Membrane H-score Cytoplasm H-score Best response* PFS (months) OS (months) Comment
a ADENO 150 95 UPR 6.3 38.7
b ADENO 100 150 NASS 2.8 2.8
c NSCLC, NOS** 65 100 NASS 7.3 16.3
d LARGE 40 30 PR 8.6 16.9 Scant/cell block ∼20 cells
e ADENO 100 75 INC 3.2 5.3
f ADENO 60 105 NA 13.8 27.0
g NSCLC, NOS 120 55 UPR 9.6 14.3
h SQUAM 140 180 PR 23.7 24.0
i SQUAM 90 80 STA 21.9 21.9
j NSCLC, NOS 20 20 PR 5.7 6.7
k SQUAM 15 20 PR 11.5 14.1
l SQUAM 10 0 STA 3.5 4.7
*CR, complete response; UCR, unconfirmed complete response; PR, partial response; UPR, unconfirmed partial response; STA, stable; INC, increasing disease;
NASS, assessment inadequate; NA, not applicable; **NOS, not otherwise specified.
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Table 4 | Clinical studies of combined cetuximab and radiotherapy for stage III NSCLC.
ClinicalTrials Study phase,
sample size
Patient
selection (*PS)
Regimen Survival (month) Non-hematologic
**AE≥Grade 3
Swedish Lung
Cancer Study
Group (26)
Phase 2
N =71
Good PS Induction
docetaxel/cisplatin×2 then
concurrent cetuximab/RT
(68/2 Gy)
MS 17 mo. OS 66% at
1-year; 37% at
2-years; 29% at
3-years
1.4% esophagitis; 5.6%
hypersensitivity; 15.4%
febrile neutropenia; 4.2% skin
reaction; 11.3% diarrhea;
4.2% pneumonitis; 1.4%
Grade 5 pneumonitis
CALGB 30407
(25)
Randomized
phase 2
N =48(arm A)
N =53 (arm B)
Good PS Arm A: carbo/pemetrexed×4,
then concurrent ChemoRT
(70/2 Gy), then pemetrexed
OS at 18 mo. 58%
Arm A, vs. 54% Arm B
Arm A: 52%; rm B: 62%;
(including esophagitis,
dysphagia, fatigue
pneumonitis, dehydration,
***N/V) 4% Grade 5 AE-Arm
A, 5.7% Grade 5 AE-Arm B
Arm B: carbo/pemetrexed×4,
then weekly cetuximab and
concurrent chemoRT (70/2 Gy),
then pemetrexed
RTOG 0324
(24)
Phase 2
N =87
Good PS Cetuximab weekly,
carbo/paclitaxel/RT 63/1.8 Gy,
followed by carbo/paclitaxel×2
cycles
MS 22.7 mo.; 49.3%
OS at 2 years
8% Esophagitis; 7%
pneumonitis; 6% Grade 5 AE
The UK
SCRATCH
Study (27)
Phase 1
N =12
Good PS Platinum-based induction
chemo, followed by concurrent
weekly cetuximab/RT 64/2 Gy
OS 66.7% at 1 year 8.3% Pneumonitis; 8.3%
lethargy
NCCTG Study
N0422 (28)
Phase 2
N =57
Elderly ≥65 years/old
and good PS; and/or
<65 years/old and
poor PS
Concurrent weekly
cetuximab/RT, 60/2 Gy
MS 15.1 mo.; Median
PFS 7.2 mo.
40% Overall AE, including
fatigue, anorexia, dyspnea,
rash, dysphagia
The German
NEAR Trial (29)
Phase 2
N =30
Good PS Concurrent cetuximab/#IMRT,
66/2 Gy, followed by 13 weekly
maintenance cetuximab
MS 19.5 mo.; OS
66.7% at 1-year;
34.9% at 2-years;
Median PFS 8.5 mo.
36.7% Overall AE; 3.3%
Grade 3 pneumonitis
SWOG 0429
(current study)
Phase 1 pilot
study N =22
Poor PS, or good PS
with poor PFT and
co-morbidities
Concurrent cetuximab/RT
(64.8/1.8 Gy) followed by
weekly cetuximab till 2-years or
disease progression
MS 14 mo.; OS 55%
at 1-year; Median PFS
8 mo.; PFS 18% at
1-year
22.7% Overall AE, including
18% hypomagnesemia; 9%
acne; 5% skin burn; 5%
esophagitis; 5% Grade 4
cardiac troponin/##PE
*PS. performance status.
**AE, adverse events.
***N/V, nausea/vomiting.
#IMRT, intensity modulated radiotherapy.
##PE, pulmonary emboli.
stratum 1 (> or= 5% weight loss and/or PS 2) received RT daily
2 Gy for 33 fractions (66 Gy) and gefitinib 250 mg daily. Good-
risk stratum 2 (PS 0–1, and weight loss <5%) received the same
RT with gefitinib 250 mg daily and weekly paclitaxel 50 mg/m2
plus carboplatin AUC 2. Consolidation gefitinib was adminis-
tered until disease progression. The study yielded a median PFS of
13.4 months and median OS of 19.0 months for poor-risk stratum;
and a median PSF of 9.2 months and a median OS of 13 months for
good-risk stratum. Survival for good-risk patients receiving con-
current chemoRT plus gefitinib was disappointing even for tumors
with active EGFR mutations. This finding highlighted the potential
adverse consequences from chemotherapy-related toxicity even in
good-risk patients.
To date, there were six phase 2 national and international stud-
ies published using cetuximab as part of the treatment for stage III
NSCLC (24–29). Five of the six studies were designed for patients
with good PS, and one study has allowed both good performance
elderly (79%) and younger patients with poor performance (21%)
(Table 4). Four of the six studies have combined cetuximab with
chemotherapy and radiation treatments, while only two studies
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combined cetuximab with RT only. Of the two, the study by Jensen
et al. (29) applied IMRT to a total dose of 66 Gy in 2 Gy daily
fractions in combination with concomitant as well as 13 weekly
maintenance cycles of cetuximab. Patients in this study had slightly
favorable baseline prognostic factors (inclusion of some stage II
patients, no weight loss>5%, and younger median age). This study
yielded a median survival of 19 months and a response rate of 63%.
The other study by Jatoi et al. (28) applied concurrent cetuximab
with 60 Gy in 2 Gy daily fractions of chest RT for patients ages
≥65 years with PS 0–1, or <65 years old with PS of 2. This study
yielded a median survival of 17 months, and a 26% response rate.
It is clear that all published work of poor-risk patients, elderly
patients, and patients treated with combination cetuximab and
RT varied in the eligibility criteria of patient selection (Table 4)
(24–29). Patient selection bias in phase 1 and 2 studies can con-
found the interpretation of therapy outcome. Our study was not
designed to measure survival as the primary endpoint, and we were
fully aware of the limitation of data interpretation from the small
sample size in a pilot phase 1 study. Further studies with larger
sample sizes will be useful to establish the optimal therapeutic ratio
of this regimen. Nevertheless, the median survival of 14 months
of our study compared favorably to the two previous SWOG tri-
als for similar eligible patients of poor-risk, stage III population.
The slow accrual was primarily due to the individual preferences
of therapy regimen by oncologists of SWOG participating institu-
tions in treating poor-risk stage III NSCLC. Defining the optimal
therapy for poor-risk stage III NSCLC remains a challenge to
oncologists.
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